Minimed Group, Inc. (MMED) Releases Q3 2026 Earnings: Revenue Growth but Operating Loss

By: Quiver EarningsTracker

Posted: 9 hours ago / April 17, 2026 8:48 p.m. UTC

MMED

Minimed Group, Inc. ($MMED) reported third-quarter 2026 results with top-line growth alongside margin pressure and an operating loss.

Key income statement highlights:

Total revenue: $790 million (+14.99% year-over-year).

Gross profit: $362 million (-8.35% year-over-year).

Cost of sales: $428 million (+46.58% year-over-year).

Operating result: operating loss of $100 million (-576.19% year-over-year).

Net loss attributable to common shareholders: $119 million (change +1090.0% year-over-year); diluted loss per share: $0.47 (change +1075.0% year-over-year).

Cash flow and balance sheet highlights:

Cash from operating activities: $66 million (+175.0% year-over-year).

Purchases of property, plant and equipment (capex): $53 million (+6.0% year-over-year).

Cash and cash equivalents: $8 million (-27.27% year-over-year).

Total liabilities: $729 million (-16.3% year-over-year).

In summary, Minimed delivered solid revenue growth but faced wider cost pressure that reduced gross profit and produced an operating and net loss; operating cash generation strengthened, while the company’s cash balance remained modest and liabilities declined year-over-year.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Minimed Group, Inc. Analyst Ratings

Wall Street analysts have issued reports on $MMED in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

William Blair issued a "Outperform" rating on 03/31/2026

To track analyst ratings and price targets for Minimed Group, Inc., check out Quiver Quantitative's $MMED forecast page.

Minimed Group, Inc. Price Targets

Multiple analysts have issued price targets for $MMED recently. We have seen 9 analysts offer price targets for $MMED in the last 6 months, with a median target of $23.0.

Here are some recent targets:

Matt Miksic from Barclays set a target price of $26.0 on 04/01/2026
Marie Thibault from BTIG set a target price of $25.0 on 03/31/2026
Anthony Petrone from Mizuho set a target price of $21.0 on 03/31/2026
Larry Biegelsen from Wells Fargo set a target price of $26.0 on 03/31/2026
Kallum Titchmarsh from Morgan Stanley set a target price of $19.0 on 03/31/2026
Daniel Markowitz from Evercore ISI Group set a target price of $20.0 on 03/31/2026
Travis Steed from B of A Securities set a target price of $27.0 on 03/31/2026